New hope for cervical cancer? drug cocktail targets tumors that resist immunotherapy

NCT ID NCT07186868

Not yet recruiting Disease control Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy, with or without a blood-vessel-blocking drug, in 25 women whose recurrent or metastatic cervical cancer has worsened after prior PD-1/PD-L1 treatment. The goal is to see how many patients' tumors shrink or disappear. All participants receive the same treatment, and researchers will monitor side effects and survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: iparomlimab and tuvonralimab (QL1706) plus nab-paclitaxel, with or without bevacizumab
What this could lead to: If successful, this could offer a new treatment option for women with cervical cancer that has stopped responding to standard immunotherapy.
What could go wrong: This is a very early, small study with only 25 participants and no comparison group. The combination may cause significant side effects, and results may not apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer cervical carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CERVICAL CANCER RECURRENT CERVICAL CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.